Treatment Options for Rheumatoid Arthritis: Celecoxib,Leflunomide,Etanercept,and Infliximab

Abstract

Spanish

French

OBJECTIVE:

To review new pharmacologic agents approved for use in the management of rheumatoid arthritis (RA).

DATA SOURCES:

A MEDLINE search (1966–January 2000) was conducted to identify English-language literature available on the pharmacotherapy of RA, focusing on celecoxib, leflunomide, etanercept, and infliximab. These articles, relevant abstracts, and data provided by the manufacturers were used to collect pertinent data.

STUDY SELECTION:

All controlled and uncontrolled trials were reviewed.

DATA EXTRACTION:

Agents were reviewed with regard to mechanism of action, efficacy, drug interactions, pharmacokinetics, dosing, precautions/contraindications, adverse effects, and cost.

DATA SYNTHESIS:

Traditional pharmacologic treatments for RA have been limited by toxicity, loss of efficacy, or both. Increasing discoveries into the mechanisms of inflammation in RA have led to the development of new agents in hopes of addressing these limitations. With the development of celecoxib, a selective cyclooxygenase-2 inhibitor, the potential exists to minimize the gastrotoxicity associated with nonsteroidal antiinflammatory drugs. Leflunomide has been shown to be equal to or less efficacious than methotrexate, and may be beneficial as a second-line disease-modifying antirheumatic drug (DMARD). The biologic response modifiers, etanercept and infliximab, are alternatives that have shown benefit alone or in combination with methotrexate. However, they should be reserved for patients who fail to respond to DMARD therapy. Further studies should be conducted to evaluate the long-term safety and efficacy of these agents as well as their role in combination therapy.

CONCLUSIONS:

Celecoxib, leflunomide, etanercept, and infliximab are the newest agents approved for RA. Clinical trials have shown that these agents are beneficial in the treatment of RA; however, long-term safety and efficacy data are lacking.

Keywords

rheumatoid arthritis celecoxib leflunomide etanercept infliximab

Get full access to this article

View all access options for this article.

References

American College of Rheumatology Ad Hoc Committee on Clinical Guidelines. Guidelines for the management of rheumatoid arthritis. Arthritis Rheum 1996;39:713–22.

Harris

. Rheumatoid arthritis: Pathophysiology and implications for therapy. N Engl J Med 1990;322:1277–89.

Yelin

Henke

Epstein

. The work dynamics of the person with rheumatoid arthritis. Arthritis Rheum 1987;30:507–12.

Makisara

. Prognosis of functional capacity and work capacity in RA. Clin Rheumatol 1982;1:117–25.

Pincus

Callahan

Vaughn

. Questionnaire, walking time and button test measures of functional capacity as predictive markers for mortality in rheumatoid arthritis. J Rheumatol 1987;114:240–51.

Package insert. Vioxx (rofecoxib). Whitehouse Station, NJ: Merck & Co., May 1999.

Moreland

. Inhibitors of tumor necrosis factor: New treatment options for rheumatoid arthritis. Cleve Clin J Med 1999;66:367–74.

Felson

Anderson

Boers

Bombardier

Chernoff

Fried

The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. Arthritis Rheum 1993;36:729–40.

Felson

Anderson

Boers

Bombardier

Furst

Goldsmith

American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727–35.

10.

Paulus

Egger

Ward

Williams

, the Cooperative Systemic Studies of Rheumatoid Diseases Group. Analysis of improvement in individual rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs, based on the findings in patients treated with placebo. Arthritis Rheum 1990;33:477–84.

11.

Mallya

Mace

BEW

. The assessment of disease activity in rheumatoid arthritis using a multivariate analysis. Rheumatol Rehabil 1981;20: 14–7.

12.

Larsen

Dale

Eck

. Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films. Acta Radiol 1977;18:481–91.

13.

van der Heijde

. How to read radiographs according to the Sharp/van der Heijde method. J Rheumatol 1999;26:743–5.

14.

Lipsky

Isakson

. Outcome of specific COX-2 inhibition in rheumatoid arthritis. J Rheumatol 1997;24(suppl 49):9–14.

15.

Vane

Bakhle

Botting

. Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol 1998;38:97–120.

16.

Hubbard

Keopp

Talwalker

Geis

. Pilot efficacy of SC-58635, a COX-2 selective inhibitor, in rheumatoid arthritis (abstract). Arthritis Rheum 1997;40:S51.

17.

Simon

Lanza

Lipsky

Hubbard

Talwalker

Schwartz

Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: Efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects. Arthritis Rheum 1998;41(suppl 9): 1591–602.

18.

Data on file. Celebrex (celecoxib). Celecoxib formulary information: efficacy data. Skokie, IL: Searle & Co., February 1999.

19.

Simon

Weaver

Graham

Kivitz

Lipsky

Hubbard

Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis. JAMA 1999;282:1921–9.

20.

Emery

Zeidler

Kvien

Guslandi

Naudin

Stead

Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: Randomized double-blind comparison. Lancet 1999;354:2106–11.

21.

Karim

Tolbert

Burton

Piergies

Harper

Paulson

SC-58635 (celecoxib): A highly selective inhibitor of cyclooxygenase-2. Disposition kinetics in man and identification of its major CYP450 isozyme in its biotransformation (abstract). Pharm Res 1997;14(suppl 11):S617.

22.

Package insert. Celebrex (celecoxib). Skokie, IL: Searle & Co., October 1999.

23.

Michalets

. Update: Clinically significant cytochrome P-450 drug interactions. Pharmacotherapy 1998;18:84–112.

24.

Data on file. Celebrex (celecoxib). Drug interactions (cele-1-018/ 1121427/362744/2). Skokie, IL: Searle & Co., May 1999.

25.

Karim

Tolbert

Piergies

Hunt

Hubbard

Harper

Celecoxib, a specific COX-2 inhibitor, lacks significant drug—drug interactions with methotrexate or warfarin (abstract). Arthritis Rheum 1998;41(suppl 9):S315.

26.

Food and Drug Administration. Letter — Celebrex. May 1999 [cited 2000 Jan 16]. Available from: URL: http://www.fda.gov/medwatch/safety/1999/celebr.htm#celebr.

27.

Data on file. Celebrex (celecoxib). Gastrointestinal safety data (cele-1-004/1121427/362744/1). Skokie, IL: Searle & Co., May 1999.

28.

Data on file. Celebrex (celecoxib). Treatment of rheumatoid arthritis (cele-1-032/1121427/362744/8). Skokie, IL: Searle & Co., May 1999.

29.

1999 Drug topics red book. Montvale, NJ: Medical Economics, 1999.

30.

Package insert. Arava (leflunomide). Kansas City, MO: Hoechst Marion Roussel, September 1998.

31.

Fox

. Mechanism of action of leflunomide in rheumatoid arthritis. J Rheumatol 1998;25(suppl 53):20–6.

32.

Mladenovic

Domljan

Rozman

Jajic

Mihajlovic

Dordevic

Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis. Arthritis Rheum 1995;38:1595–603.

33.

Smolen

Kalden

Scott

Rozman

Kvien

Larsen

Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: A double-blind, randomized, multicentre trial. Lancet 1999;353:259–66.

34.

Smolen

Larsen

Kalden

Scott

Oed

Rosenburg

Retardation of structural damage with leflunomide in rheumatoid arthritis assessed by Larsen methodology: 2-year results (abstract). Arthritis Rheum 1999;42(suppl 9):S82.

35.

Drosos

Tsifetaki

Tsiakou

Timpanidou

Tsampoulas

Tatsis

Influence of methotrexate on radiographic progression in rheumatoid arthritis: A sixty-month prospective study. Clin Exp Rheumatol 1997;15:263–7.

36.

Data on file. Arava (leflunomide). Arava — comparison to methotrexate. Kansas City, MO: Hoechst Marion Roussel, April 1999.

37.

Strand

Cohen

Schiff

Weaver

Fleischmann

Cannon

Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Arch Intern Med 1999;159:2542–50.

38.

Cohen

Weaver

Schiff

Strand

. Two-year treatment of active rheumatoid arthritis (RA) with leflunomide (Lef) compared with placebo (PL) or methotrexate (MTX) (abstract). Arthritis Rheum 1999;42(suppl 9):S271.

39.

Emery

Breedveld

Jubb

Sorensen

Oed

Leeds

Efficacy and safety of leflunomide vs. methotrexate in rheumatoid arthritis (RA): Results of a double-blind, randomized, 2-year trial (abstract). Arthritis Rheum 1999;42(suppl 9):S271.

40.

O'Dell

. Methotrexate use in rheumatoid arthritis. Rheum Dis Clin North Am 1997;23:779–96.

41.

Kremer

. Methotrexate update. Scand J Rheumatol 1996;25:341–4.

42.

Data on file. Arava (leflunomide). Arava — combination with methotrexate. Kansas City, MO: Hoechst Marion Roussel, April, 1999.

43.

Weinblatt

Kremer

Coblyn

Maier

Helfgott

Morrell

Combination therapy with leflunomide—methotrexate in refractory rheumatoid arthritis (abstract). In: Proceedings of European League Against Rheumatism, Geneva, Switzerland, September 5–8, 1998:156.

44.

Weinblatt

Kremer

Coblyn

Maier

Helfgott

Morrell

Pharmacokinetics, safety, and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis. Arthritis Rheum 1999;42:1322–8.

45.

Rozman

. Clinical experience with leflunomide in rheumatoid arthritis. J Rheumatol 1998;25(suppl 53):27–32.

46.

Lipsky

. Rheumatoid arthritis. In: Fauci

Braunwald

Isselbacher

Wilson

Martin

Kasper

, eds. Harrison's principles of internal medicine. 14th ed. New York: McGraw-Hill, 1998:1880–8.

47.

Package insert. Enbrel (etanercept). Seattle, WA: Immunex, May 1999.

48.

Moreland

Baumgartner

Schiff

Tindall

Fleischmann

Weaver

Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997;337:141–7.

49.

Moreland

Schiff

Baumgartner

Tindall

Fleischmann

Bulpitt

Etanercept therapy in rheumatoid arthritis: A randomized, controlled trial. Ann Intern Med 1999;130:478–86.

50.

Weinblatt

Moreland

Schiff

Baumgartner

Tindall

Fleischmann

Long-term and Phase III treatment of DMARD failing rheumatoid arthritis patients with TNF receptor p75 Fc fusion protein (TNRF: FC, Enbrel) (abstract). Arthritis Rheum 1997;40(suppl): S126.

51.

Moreland

Baumgartner

Tindall

Schiff

Fleischmann

Weaver

Long-term safety and efficacy of TNF receptor (p75) Fc fusion protein (TNRF:FC, Enbrel) in DMARD refractory rheumatoid arthritis (RA). Presented at the 1998 National Scientific Meeting of the American College of Rheumatology, San Diego, CA, November 12, 1998.

52.

Weinblatt

Kremer

Bankhurst

Bulpitt

Fleischmann

Fox

A trial of etanercept, a recombinant tumor necrosis factor receptor: FC fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999;340:253–9.

53.

Weinblatt

Kremer

Lange

Burge

. Long-term safety and efficacy of combination therapy with methotrexate (MTX) and etanercept (Enbrel) (abstract). Arthritis Rheum 1999;42(suppl):S401.

54.

Food and Drug Administration. FDA Talk Paper T99–22: new warning for arthritis drug, Enbrel [cited 1999 May 12]. Available from: URL: http://www.fda.gov/bbs/topics/ANSWERS/ANS00954.html.

55.

Data on file. Enbrel (etanercept) Etanercept — antibody formation. Malvern, PA: Centocor, 1999.

56.

Data on file. Enbrel (etanercept) Etanercept — autoantibodies. Malvern, PA: Centocor, 1999.

57.

Package insert. Remicade (infliximab). Malvern, PA: Centocor, November 1999.

58.

Elliot

Maini

Feldmann

Long-Fox

Charles

Katsikis

Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor a. Arthritis Rheum 1993;36:1681–90.

59.

Elliot

Maini

Feldmann

Long-Fox

Charles

Bijl

Repeated therapy with monoclonal antibody to tumor necrosis factor (cA2) in patients with rheumatoid arthritis. Lancet 1994;344:1125–7.

60.

Keystone

. The role of tumor necrosis factor antagonism in clinical practice. J Rheumatol 1999;26(suppl 57):22–8.

61.

Elliot

Maini

Feldmann

Kalden

Antoni

Smolen

Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor (cA2) versus placebo in rheumatoid arthritis. Lancet 1994;344:1105–10.

62.

Kavanaugh

Cush

St. Clair

McCune

Braakman

TAJ

Nichols

Anti-TNF- monoclonal antibody (mAb) treatment of rheumatoid arthritis (RA) patients with active disease on methotrexate (MTX); results of a double-blind, placebo controlled multicenter trial (abstract). Arthritis Rheum 1996;39(suppl):S123.

63.

Kavanaugh

Cush

St. Clair

McCune

Braakman

TAJ

Nichols

Anti-TNF- monoclonal antibody (mAb) treatment of rheumatoid arthritis (RA) patients with active disease on methotrexate (MTX); results of open label, repeated dose administration following a single dose, double-blind, placebo controlled trial (abstract). Arthritis Rheum 1996;36(suppl):S244.

64.

Maini

Breedveld

Kalden

Smolen

Davis

Macfarlane

Therapeutic efficacy of multiple intravenous infusions of antitumor necrosis factor- monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998;41: 1552–63.

65.

Rezaian

. Do infliximab and methotrexate act synergistically in the treatment of rheumatoid arthritis? Comment on the article by Maini, et al. (letter). Arthritis Rheum 1999;42:1779–81.

66.

Maini

St. Clair

Breedveld

Furst

Kalden

Weisman

Infliximab (chimeric anti-tumour necrosis factor a monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomised Phase III trial. Lancet 1999;354:1932–9.

67.

Lipsky

St. Clair

Furst

Breedveld

Smolen

Kalden

54-week clinical and radiographic results from the ATTRACT trial: A phase III study of infliximab (Remicade) in patients with active RA despite methotrexate (abstract). Arthritis Rheum 1999;42(suppl):S401.

68.

Data on file. Remicade (infliximab) Remicade — ATTRACT trial (53802). Malvern, PA: Centocor, 1999.

69.

Doctor's Guide. ACR: Remicade may stop the progression of RA [cited 1999 Nov 18]. Available from: URL: http://www.pslgroup.com/dg/14/45a.htm.

70.

Data on file. Remicade (infliximab) Remicade — infection (44232). Malvern, PA: Centocor, 1999.